Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind everyone that we ...
Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Hosted on MSN1mon
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transitionEarnings Call Insights: Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Christophe Weber, CEO, announced his retirement effective June 2026 after a 12-year tenure. Julie Kim, President of ...
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments ...
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...
$380,000 of TAKEDA PHARMACEUTICALS AMERICA INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "H.R. 8239, Agriculture ...
SANYA, China — Rio Takeda of Japan shot a 3-under 69 on Saturday to hold a two-shot lead after three rounds of the LPGA’s Blue Bay tournament on China’s southern island of Hainan. Takeda was on ...
On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.
SANYA, China (AP) — Rio Takeda of Japan shot a 3-under 69 on Saturday to hold a two-shot lead after three rounds of the LPGA's Blue Bay tournament on China's southern island of Hainan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results